title: Has the cost-effectiveness of Xolair (omalizumab) been underestimated?
authors.forename: Carl V
authors.initials: CV
authors.lastname: Asche
authors.forename: Diana I
authors.initials: DI
authors.lastname: Brixner
authors.forename: Gary M
authors.initials: GM
authors.lastname: Oderda
mesh_terms: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D002985:Clinical Protocols; D003365:Costs and Cost Analysis; D006801:Humans; D000069444:Omalizumab; D012106:Research
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab